They cannot explain, however, the major result of a 'particularly low relapse rate' in the AMLCG trial restricted to 16-60 years of age. Sanz and colleagues failed to demonstrate age as a risk factor of relapse in the combined Italian and Spanish data.
Response to Lengfelder et al
In our opinion, the excellent results in terms of antileukemic efficacy reported by Lengfelder et al do not support some of the original paper's statements, which they repeat in their extended reply. To deal in specific detail with all of the nine points argued by Lengfelder et al would be too exhaustive, so we will address some selected issues. For example, when examining the data for toxicity and compliance, the AMLCG study showed that, in four of the 45 patients (9%) consolidation was omitted due to severe infections during induction. over, 13 patients (29%) did not receive maintenance therapy (including the four patients that had not received consolidation). In 11 additional cases (24%), maintenance therapy was terminated early. This significant lack of compliance was mainly due to toxicity, leading to refusal by the patients in 31%; physicians' decision after previous severe infections in 26%; prolonged neutropenia between courses in 31%; chronic hepatitis in 6%; and vasculitis in a further 6%. In our opinion, only the enthusiasm generated by the antileukemic efficacy of the AMLCG protocol, but not by such telling data on toxicity and compliance, could lead Lengfelder et al to claim 'the treatment was feasible with an acceptable toxicity and a good compliance'. Our counts for the cumulative dose of anthracyclines administered in the AMLCG study, in comparison with other protocols, are slightly different to those counted by Lengfelder et al. It is true that the cumulative DNR equivalent dose given during induction and consolidation in the AMLCG study was 485 mg/m 2 , but maintenance therapy was scheduled to reach a cumulative DNR dose of 540 mg/m 2 . However, the cumulative DNR equivalent dose given in the GIMEMA and PETHEMA studies was clearly lower (440 mg/m 2 ). How can Lengfelder et al rule out the impact of this and other factors on their results and state it was essentially due to 'an ara-C effect'?
We feel that Lengfelder et al do not take into account that, due to the small sample size, all estimates in the AMLCG study show wide confidence intervals (CI). Thus, although the reported overall, eventfree and relapse-free survival rates at 2 years by Lengfelder et al (88% ± 9%, 88% ± 9% and 96% ± 6%, respectively) appear to be better than those reported by the PETHEMA study (82% ± 4%, 79% ± 4% and 92% ± 3%), the much wider CI of the AMLCG series suggests that these differences are not significant. Additionally, while to extend this reply to other considerations would make it endless, we insist that legitimate comparisons between APL series must be done in terms of
Response to Sanz et al
In this discussion addressing diverse aspects of APL treatment, it should be kept in mind that the usefulness of a potent chemotherapy in addition to ATRA is suggested by the fact that cure cannot be achieved with ATRA alone. Therefore, it was the main aim of our treatment protocol to investigate the effects of ATRA combined with an intensive chemotherapy regimen with proven high antileukemic efficacy in APL (double induction including high-dose ara-C, consolidation and maintenance therapy). 1 Intensive chemotherapy regimens are generally associated with treatment-related toxicity.
Dr Sanz and colleagues overstress the issue of toxicity and compliance in our trial. Our regimen of double induction using high-dose ara-C and ATRA resulted in spite of its intensity in only 8% early death and 4% death in remission 1 as compared with 10% early death in the Spanish trial.
2 Ninety-one percent of the responders in our study received consolidation and 71% of them received maintenance treatment. 1 Omissions or premature terminations of treatment were no protocol violations and do not reflect poor compliance. Even with these treatment adaptations and an evaluation according to intent-to-treat the relapse rate is the lowest relapse rate after 3 years known from the literature.
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